Pfizer, BioNTech start study testing next COVID-19 vaccine

Pfizer and BioNTech on Thursday announced the start of a Phase 1 study of a new COVID-19 vaccine candidate designed to spur a broader and potentially more durable immune response. The study will enroll healthy adults who have taken at least three doses of an mRNA-based vaccine and will evaluate the new shot’s safety and immunogenicity.